Article
Modernizing Quality in the Cloud
For decades, costly regulatory issues bore witness to pharma’s reactive approach to quality. Billion-dollar consent decrees, caused by fundamental quality failures, drove some manufacturers out of business, while regulators continued to find fault with practices ranging from inadequate CAPA and root-cause analysis to insufficient contract partner oversight.